Letters to the Editor

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Birmingham, Birmingham, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK;
University of Liverpool, Liverpool, UK;
University of Liverpool, Liverpool, UK;
Univ of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK;
Univ of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK;
Univ of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK;
Univ of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK;
The Royal Bournemouth Hospital, Bournemouth, UK;
The Christie NHS Foundation Trust, Manchester, UK;
Churchill Hospital, Oxford, UK;
Southampton General Hospital, Southampton, UK;
Royal Marsden NHS Foundation Trust, Sutton, UK;
University Hospital of Wales, Cardiff, UK;
Leicester Royal Infirmary, Leicester, UK;
The Royal Bournemouth Hospital, Bournemouth, UK;
City Hospitals Sunderland NHS Trust, Sunderland, UK;
Nottingham University Hospitals NHS Trust, Nottingham, UK;
University of Leeds, Leeds, UK
Haematologica Early view Feb 13, 2020 https://doi.org/10.3324/haematol.2019.230805